JACC. Advances · 2026
Prevalence and Prognostic Implications of Atherosclerotic Coronary Artery Disease in Type 2 Myocardial Infarction.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Knott Jonathan D, De Michieli Laura, Ola Olatunde, Akula Ashok, Slusser Josh, Raphael Claire, Gulati Rajiv, Jaffe Allan S, Sandoval Yader
Аннотация
BACKGROUND: Type 2 myocardial infarction (MI) (T2MI) is common and associated with adverse outcomes.
OBJECTIVES: The objective of the study was to evaluate the prevalence of coronary artery disease (CAD) in patients with T2MI and myocardial injury and its impact on outcomes.
METHODS: Observational U.S. cohort study of emergency department patients undergoing high-sensitivity cardiac troponin T measurement. Cases with >1 high-sensitivity cardiac troponin T increase >99th percentile were adjudicated following the Fourth Universal Definition of MI. CAD was defined as a prior CAD, MI, or coronary revascularization or newly diagnosed CAD during index hospitalization. Two-year major adverse cardiovascular outcomes including all-cause, cardiovascular, and noncardiovascular death, acute MI, heart failure hospitalization, and coronary revascularization were compared between patients with T2MI or myocardial injury and CAD vs type 1 MI (T1MI).
RESULTS: Among 858 patients, 64 (7.5%) had T1MI, 91 (11%) had T2MI, and 703 (82%) had myocardial injury. Patients with T2MI and CAD (n = 31; 34% of T2MI) had higher major adverse cardiovascular outcomes than T1MI (65% vs 39%; adjusted HR [aHR]: 1.95; 95% CI: 1.2-3.6), driven by higher all-cause death (52% vs 20%; aHR: 2.2; 95% CI: 1.0-4.5), noncardiovascular death (26% vs 5%; aHR: 5.04; 95% CI: 1.3-19.3), acute MI (13% vs 2%; aHR: 9.2; 95% CI: 1.01-84.2), and heart failure hospitalization (32% vs 8%; aHR: 4.6; 95% CI: 1.6-13.7). Patients with myocardial injury and CAD (n = 245) demonstrated similar trends, although differences were not statistically significant after adjustment.
CONCLUSIONS: CAD is common among patients with T2MI and myocardial injury and is associated with poor long-term outcomes. Its presence may facilitate risk-stratification and represent a potential therapeutic target.
OBJECTIVES: The objective of the study was to evaluate the prevalence of coronary artery disease (CAD) in patients with T2MI and myocardial injury and its impact on outcomes.
METHODS: Observational U.S. cohort study of emergency department patients undergoing high-sensitivity cardiac troponin T measurement. Cases with >1 high-sensitivity cardiac troponin T increase >99th percentile were adjudicated following the Fourth Universal Definition of MI. CAD was defined as a prior CAD, MI, or coronary revascularization or newly diagnosed CAD during index hospitalization. Two-year major adverse cardiovascular outcomes including all-cause, cardiovascular, and noncardiovascular death, acute MI, heart failure hospitalization, and coronary revascularization were compared between patients with T2MI or myocardial injury and CAD vs type 1 MI (T1MI).
RESULTS: Among 858 patients, 64 (7.5%) had T1MI, 91 (11%) had T2MI, and 703 (82%) had myocardial injury. Patients with T2MI and CAD (n = 31; 34% of T2MI) had higher major adverse cardiovascular outcomes than T1MI (65% vs 39%; adjusted HR [aHR]: 1.95; 95% CI: 1.2-3.6), driven by higher all-cause death (52% vs 20%; aHR: 2.2; 95% CI: 1.0-4.5), noncardiovascular death (26% vs 5%; aHR: 5.04; 95% CI: 1.3-19.3), acute MI (13% vs 2%; aHR: 9.2; 95% CI: 1.01-84.2), and heart failure hospitalization (32% vs 8%; aHR: 4.6; 95% CI: 1.6-13.7). Patients with myocardial injury and CAD (n = 245) demonstrated similar trends, although differences were not statistically significant after adjustment.
CONCLUSIONS: CAD is common among patients with T2MI and myocardial injury and is associated with poor long-term outcomes. Its presence may facilitate risk-stratification and represent a potential therapeutic target.